The Prognostic Values of m6A RNA Methylation Regulators in Thyroid Carcinoma

Di Zhang

Tianjin Tumor Hospital

Yue Ma

Tianjin Tumor Hospital

Xu-Chen Cao

Tianjin Tumor Hospital

Li Fu

Tianjin Tumor Hospital

Yue Yu (✉ yuyue@tmu.edu.cn)

Tianjin Medical University Cancer Institute and Hospital <https://orcid.org/0000-0003-2053-9866>

Xin Wang

Tianjin Tumor Hospital

Primary research

Keywords: thyroid carcinoma, m6A RNA methylation regulator, TCGA, gene signature, prognosis

Posted Date: August 14th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-56381/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: N6-methyladenosine (m6A) is the most common RNA modification and regulates RNA splicing, translation, translocation, and stability. Aberrant expression of m6A has been reported in various types of human cancers. m6A RNA modification is dynamically and reversibly mediated by different regulators, including methyltransferase, demethylases, and m6A binding proteins. However, the role of m6A RNA methylation regulators in thyroid cancer remains unknown. The aim of this study is to investigate the effect of the 13 main m6A RNA modification regulators in thyroid carcinoma.

Methods: The gene expression profile of m6A RNA modification regulations and clinical information of patients with thyroid carcinoma were obtained from The Cancer Genome Atlas database. Consensus clustering was applied to identify two clusters of thyroid carcinomas with different clinical outcome. LASSO Cox regression analysis was used to construct gene-based prognostic signature based on the expression of m6A RNA methylation regulators. Kyoto Encyclopedia of Genes and Genomes, Gene Ontology and gene set enrichment analyses were performed to explore differential cellular processes and signaling pathways between the two groups based on risk signature.

Results: We found that most of the m6A RNA modification regulators are down-regulated in 450 patients with thyroid carcinoma. We identified two clusters based on the gene expression profiles of 13 m6A RNA modification regulators using consensus clustering. The cluster 2 subgroup correlates with an unfavorable outcome compared with the cluster 1 subgroup. In addition, we derived a three m6A RNA modification regulator genes-based risk signature (FTO, RBM15 and KIAA1429), that is an independent prognostic biomarker in patients with thyroid carcinoma. There were significantly different signaling pathways between high and low risk group by Kyoto Encyclopedia of Genes and Genomes, Gene Ontology and gene set enrichment analyses. Moreover, we found that this risk signature could better predict outcome in male than female.

Conclusion: Our study revealed the prognostic value of m6A RNA methylation regulators in patients with thyroid carcinoma.

Introduction

Thyroid carcinoma is one of the most prevalent human malignancies, and its incidence has significantly increased over the past ten years [1]. According to the histological characteristics, thyroid carcinoma can be classified into four types, including anaplastic, follicular, medullary, and papillary thyroid carcinoma [2]. Although thyroid cancer has been considered a disease with favorable outcome, the patients with advanced thyroid carcinoma have a poor 5-year survival rate [3-4]. Therefore, it is important to identify effective diagnostic markers, prognostic indicator and therapeutic targets for thyroid carcinoma treatment.

N6-methyladenosine (m6A), a modification occurs at the N6 position of RNA adenine (A), is the most abundant modification on RNA molecules. m6A was first discovered in 1974, occurring in various types

of RNAs, including mRNA, tRNA, snRNA, and long noncoding RNA [5-6]. The m6A methylation is the most prevalent and well recognized modification among all RNA modifications. Similar to DNA methylation, m6A methylation regulates the post-transcriptional expression of target RNAs by affecting RNA alternative splicing, stability, nuclear export, mRNA decay, and translation [7-10]. Its regulatory effects are mediated by the dynamic and reversible interactions among methyltransferases (“writers”), demethylase (“erasers”) and RNA-binding proteins (“readers”), which can add, remove, and recognize m6A-modified sites and generate different functions [11]. Methyltransferases, known as the “writers”, are composed of METTL3/14/, RBM15, WTAP, KIAA1429, and ZC3H13, regulating the process of methylated modification of RNA. Demethylase, which are considered m6A “erasers”, consist of FTO and ALKBH5, mediating the demethylation process of RNA. RNA-binding proteins, known as m6A “readers”, recognize RNA methylated information and participate in the translation and degradation of downstream RNA, including YTHDC1, YTHDC2, YTHDF1, YTHDF2, and HNRNPC. Increasing studies have shown that abnormal m6A modification plays an important role during tumorigenesis and progression in a variety types of human cancers, including oral squamous cell carcinoma, acute myeloid leukemia (AML), glioblastoma, hepatocellular carcinoma, pancreatic cancer and breast cancer [12-18]. However, the association between m6A RNA modification regulators and thyroid carcinoma remains unknown.

In present study, we identified that 13 m6A RNA methylation regulators were abnormally expressed in thyroid carcinoma tissues compared to those in normal tissues from The Cancer Genome Atlas (TCGA) thyroid carcinoma database. Based on the signature of 13 m6A genes, we divided patients into two clusters by consensus clustering method and compared the clinical outcomes of two clusters. The Via Cox univariate analysis, the least absolute shrinkage and selection operator (LASSO) Cox regression analysis was employed to construct a prognostic gene signature with three m6A methylation regulatory genes. The differences in the biological pathways were also explored by Kyoto Encyclopedia Genes and Genomes (KEGG), Gene Ontology (GO) and gene set enrichment analysis (GSEA) between subgroups with different prognosis. Our results emphasized the significance of m6A methylation-related genes in thyroid cancer and established a prognostic gene signature for predicting the prognosis in patients with thyroid cancer.

Materials And Methods

Dataset

All data were obtained from the TCGA database (<https://portal.gdc.cancer.gov/>), containing RNA-seq transcriptome data and the corresponding clinicopathological information on 450 thyroid carcinoma patients (450 cases of tumor tissues and 58 cases of normal tissues; Table S1).

Differential expression analysis of m6A RNA methylation regulators

Limma package and wilcox-test were used for screening the differentially expressed genes (DEGs) between tumor tissues and normal tissues. We extracted the expression matrix of the 13 known m6A RNA methylation regulators, including METTL3, YTHDF1, KIAA1429, YTHDC2, ALKBH5, YTHDF2, YTHDC1,

ZC3H13, METTL14, FTO, WTAP, RBM15 and HNRNPC. Heatmap and vioplot were used to display the different expression of the 13 m6A RNA methylation regulators in normal tissues and tumor tissues. Pearson correlation analysis was used to evaluate the association among different m6A RNA methylation regulators with “corrplot” R package.

Consensus clustering analysis

The TCGA thyroid carcinoma cohort was divided into different clusters by consensus expression of m6A RNA methylation regulators with “ConsensusClusterPlus” R package [19]. Principal component analysis (PCA) was performed by limma and ggplot2 package. Kaplan-Meier survival curves and the log-rank test were used to evaluate patients of thyroid carcinoma with different clusters. Chi-square test was used to compare the distribution of age, gender and stage between different clusters.

Prognostic signatures construction and prediction

Univariate Cox analysis was performed to assess the prognostic value of m6A RNA methylation regulators. Regulators with a hazard ratio (HR) < 1 or > 1 were considered as protective or risk genes, respectively. The LASSO Cox regression algorithm was used to construct the optimal prognostic model out of the 13 m6A regulators. A risk score for each patient was calculated as the sum of each gene's score, which was obtained by multiplying the expression of each gene and its coefficient. We divided the patients from the TCGA thyroid carcinoma cohort into high-risk and low-risk groups based on their risk scores being below or above the median value. The survival difference in overall survival between high-risk group and low-risk group was analyzed by the Kaplan-Meier method with a two-sided log-rank test. Receiver operating characteristic (ROC) curve was constructed to evaluate the accuracy of the model prediction. Chi-square test was performed to compare the differences of clinicopathological features between high-risk group and low-risk group. Heatmaps were generated using the pheatmap R package and used to visualize the differences. Univariate and multivariate Cox regression analyses were used to identify the independent prognostic factors for the TCGA thyroid carcinoma cohort. The survival difference between high-risk group and low-risk group subgrouped by age, gender, tumor size and stage was further evaluated.

Signaling pathways and cellular processes affected by m6A regulators

GSEA was used to explore the biological pathways underlying the high-risk and low-risk groups defined by the prognostic signature in the thyroid carcinoma patients. KEGG gene sets (v7. 0) and phenotype label (HighRisk vs. LowRisk) files were generated and loaded into the GSEA software (v4.0.3; Broad Institute, Cambridge, MA). The permutation test run 1, 000 times. The GO and KEGG pathway enrichment analyses were applied for exploring the relevant signaling pathways enriched by DEGs between the high-risk group and the low-risk group using clusterProfiler R package.

Statistical analysis

Data analysis was performed with the R v3.6.1. All statistical tests were two-sided. A P value of less than 0.05 was considered statistically significant.

Results

Patient demographics and tumor characteristics

The thyroid carcinoma cohort was downloaded from TCGA and the clinicopathological characteristics of patients were listed in Table S1. Only cases with clinicopathological and prognostic information were included in this study (n = 450).

The landscape of m6A RNA methylation regulators in thyroid carcinoma

To investigate the role of m6A RNA methylation regulators in thyroid carcinoma development and progression, we first determined the expression levels of 13 m6A RNA methylation regulators 450 thyroid carcinoma tissues and 58 normal thyroid tissues from TCGA dataset by heatmap (Fig. 1A). We observed that the expression level of 11 m6A RNA methylation regulators (METTL3, METTL14, RBM15, WTAP, YTHDC1, YTHDC2, YTHDF1, KIAA1429, FTO, ZC3H13 and ALKBH5) was significantly decreased in thyroid carcinoma tissues compared to those in normal thyroid tissues, whereas the expression level of HNRNPC was increased in thyroid carcinoma tissues (Fig. 1B). The alternation of m6A RNA methylation regulators ratio is an intrinsic feature that can characterize individual differences [20]. The correlations between 13 m6A RNA methylation regulators were analyzed by Spearman correlation analysis. As shown in Fig. 1C, the relationship between the 13 m6A RNA methylation regulators was weakly to strongly positively correlated. Moreover, the METTL14 gene was most strongly correlated with KIAA1429 and YTHDC1 genes ($r = 0.78$), and the ZC3H13 gene and the KIAA1429 gene were also most relevant ($r = 0.78$). In addition, we investigated the association between each individual m6A RNA methylation regulator and the clinicopathological factors of patients with thyroid cancer, including age, gender, stage, tumor size, lymph node status and metastasis and found a robust relationship between m6A RNA methylation regulator and clinicopathological factors of patients with thyroid cancer (Fig. 1D).

Consensus clustering of m6A RNA methylation regulators identified two subgroups of thyroid carcinoma

To provide insight into the clinical relevance of m6A RNA methylation regulators in thyroid carcinoma, we divided the patients into subgroups based on the expression of m6A RNA methylation regulators. "k" was used to represent the number of subgroups (Fig. 2A and 2B). After consensus clustering analysis, $k = 2$ was regarded as the most appropriated selection to separate the patients with thyroid carcinoma into two subgroups, namely cluster 1 (n = 231) and cluster 2 (n = 219) (Fig. 2C). To verify our classification, we analyzed the two subgroups by PCA. The results indicated that both cluster 1 subgroup and cluster 2 subgroup could be gathered together (Fig. 2D). Furthermore, we observed that the cluster 1 subgroup had a significantly favorable outcome compared with that in the cluster 2 subgroup ($P = 0.013$; Fig. 2E). There were significant differences in clinicopathological characteristics between the two groups, including gender, tumor status and lymph node status (Fig. 2F).

Prognostic value of risk signature

To better understand the prognostic role of the m6A RNA methylation regulators in thyroid carcinoma, we performed a univariate Cox regression analysis on the expression level of the 13 m6A RNA methylation regulators genes. As shown in Fig. 3A, high expression of RBM15 (HR = 4.341, 95% CI = 1.328 – 14.192, P = 0.015), FTO (HR = 1.623, 95% CI = 1.021 – 2.580, P = 0.041) and KIAA1429 (HR = 1.925, 95% CI = 1.079 – 3.434, P = 0.026) had a poor overall survival in patients with thyroid carcinoma. We next applied the LASSO Cox regression algorithm to the m6A RNA methylation regulator genes in the TCGA dataset and constructed an optimal prognostic gene signature. Three genes (RBM15, FTO and KIAA1429) were selected to construct the optimal prognostic gene signature based on the minimum criteria, and the coefficients obtained from the LASSO algorithm were used to calculate the risk score for TCGA dataset (Fig. 3B and 3C). Based on the median risk score, we separated the thyroid carcinoma patients into high- and low-risk subgroups. Although there was no significant difference in clinicopathological characteristics between the two subgroups (Fig. 3D), the high-risk subgroup had a worse overall survival in patients with thyroid carcinoma (Fig. 3E). The area under the ROC curve (AUC) was also calculated to evaluate the ability of the prediction model (Fig. 3F).

Investigation of biological pathways affected by m6ARNA methylation regulators

We next explored the biological signaling pathways underpinning the different outcome between the high-risk and low-risk subgroups by GSEA analysis. We observed an increased expression of genes involved in the following biological processes/signaling pathways in the high-risk subgroup, including ubiquitin mediated proteolysis (NES = 2.124, FDR < 0.001), Wnt signaling pathway (NES = 2.115, FDR < 0.001), mTOR signaling pathway (NES = 2.103, FDR < 0.001), TGF- β signaling pathway (NES = 2.059, FDR = 0.002), pathways in cancer (NES = 2.050, FDR = 0.002), MAPK signaling pathway (NES = 2.009, FDR = 0.04), RNA degradation (NES = 1.858, FDR = 0.013), and cell cycle (NES = 1.781, FDR = 0.021, Fig. 4A). A total of 214 differentially expressed genes ($\log$ FC > 1 and P < 0.05) were identified between the two subgroups and the differentially expressed genes were then annotated using GO (Fig. 4B) and KEGG (Fig. 4C) analyses. Several malignancy-related biological processes or signaling pathways were noticeable, including Ras signaling pathway, phosphoinositide 3-kinase (PI3K)-AKT signaling, peroxisome proliferator-activated receptor (PPAR) signaling.

The prognostic risk score was an independent prognostic factor in patients with thyroid carcinoma

Next, we performed univariate and multivariate Cox regression analyses to determine whether the risk score is an independent prognostic biomarker in patients with thyroid carcinoma. The univariate analysis showed that the age (P < 0.001, HR = 1.140, 95% CI = 1.081 - 1.203), stage (P < 0.001, HR = 2.750, 95% CI = 1.594 - 4.744), tumor size (P = 0.003, HR = 2.852, 95% CI = 1.415 - 5.746), and risk score (P < 0.001, HR = 1.007, 95% CI = 1.003 - 1.011) were significantly correlated with the overall survival (Fig. 5A). Multivariate Cox regression analysis was performed using variables significant in univariate analysis. As shown in Fig. 5B, the age (P < 0.001, HR = 1.127, 95% CI = 1.063 - 1.195) and risk score (P = 0.001, HR = 1.008, 95% CI = 1.003 - 1.012) were identified as the independent prognostic factors in patients with

thyroid carcinoma. We also determined whether the risk score are able to predict clinical prognosis in thyroid carcinoma stratified by age (Fig. 6A and 6B), gender (Fig. 6C and 6D), stage (Fig. 6E and 6F) and tumor size (Fig. 6G and 6H). We found that the risk score could predict outcome better in Male than Female (Fig. 6C and 6D).

Discussion

m6A, a member of RNA epigenetic modification families, is the most abundant mRNA modification in most eukaryotes and involves almost all steps of RNA metabolism, including splicing, stability, translocation and translation [21]. Although increasing evidence indicates that the m6A RNA methylation regulators act as both oncogene or tumor suppressor in many types of human malignant tumors by regulating the mRNA expression of tumor-related genes, the specific regulatory role of m6A RNA methylation regulators in cancer development and progression remains to be clarified. In the present study, we investigated the role of 13 m6A RNA methylation regulators in thyroid carcinoma and found that the expression of m6A RNA methylation regulators was closely associated with the outcome in patients with thyroid carcinoma.

Analyses of TCGA database revealed that most of m6A RNA methylated regulators except YTHDF2 were dysregulated in thyroid carcinoma, suggesting that m6A RNA modification plays a critical role in thyroid cancer development. Among them, only HNRNPC showed an increased expression in thyroid carcinoma tissues compared with that in normal tissues. HNRNPC, as the “readers” of m6A RNA modification, is well recognized for its regulatory roles in RNA splicing, sequence-unspecific RNA exportation, stability and translation. Abnormal increased expression of HNRNPC was observed in multiple types of tumors, including breast cancer, lung cancer, glioblastoma, and hepatocellular carcinoma [22-25]. Consistent with their work in other cancers, our results suggest that HNRNPC functions as an oncogene in thyroid carcinoma.

We identified two subgroups of thyroid carcinoma by consensus clustering based on the expression of the m6A RNA methylation regulators, and the cluster 2 subgroup associated with a poorer outcome. In addition, we constructed a risk signature by using 3 m6A RNA methylation regulators (FTO, RBM15, and KIAA1429) and the risk score is an independent prognostic biomarker in patients with thyroid carcinoma. FTO is the first mammalian RNA m6A demethylase, which belongs to the AIKB family [26-27]. Evidences have shown that FTO involves in the process of malignant tumors. FTO promotes AML carcinogenesis by enhancing the stability MYC and CEBPA mRNA [28]. In cervical cancer, FTO enhances the chemoradiotherapy-resistance by reducing the m6A modification of β -catenin [29]. KIAA1429, known as VIRMA, mainly regulates the m6A mRNA methylation in 3' UTR and near stop codon [30]. It is reported that KIAA1429 promotes breast cancer progression by regulating CDK1 [31]. RBM15 was originally described as a 5' translocation partner of the MAL gene in t (1; 22) (p13; q13) infant acute megakaryocytic leukemia. Thus, RBM15 plays an important role in hematopoietic development, and c-MYC is a potential target of RBM15 in the regulation of adult hematopoietic stem cell and megakaryocyte development [32-33]. In chronic myelogenous leukemia (CML), RBM15 promotes CML carcinogenesis

through its effect on the Notch signaling [34]. The functional and mechanistic studies of these genes should be further performed to definite its role in the carcinogenesis of thyroid carcinoma.

To explain the different prognosis of the two groups, we attempted to explore the mechanisms through GSEA and KEGG analyses. GSEA indicated that the significantly enriched gene sets in the high-risk subgroup with poor survival were some crucial signaling pathways and cellular processes, including ubiquitin mediated proteolysis, Wnt signaling pathway, mTOR signaling pathway, TGF- β signaling pathway, pathways in cancer, MAPK signaling pathway, RNA degradation, and cell cycle. KEGG analysis of differentially expressed genes between the two groups indicated that the m6A RNA methylation regulators were involved in several cancer-related signaling pathways, including PI3K-Akt signaling pathway and PPAR signaling pathway.

In conclusion, we determined the expression, potential function and prognostic value of the m6A RNA methylation regulators in thyroid carcinoma. The prognostic risk score was an independent prognostic factor in patients with thyroid carcinoma. Our study provides important evidence for further investigation of the role of m6A RNA methylation in thyroid carcinoma.

Declarations

Acknowledgements

This study was supported by the grants from National Natural Science Foundation of China (No. 81472472 and No.81502518).

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Competing interests

The authors declare that they have no competing interests

Funding

This study was supported by the National Natural Science Foundation of China (No. 81472472 and No.81502518).

Authors' contributions

YY and WX designed the study; ZD, LY, MY, FL and CXC performed the data analysis and interpreted the data; ZD, YY and WX wrote and revised the manuscript. All authors read and approved the final manuscript.

References

- 1▯ Sanabria A, Kowalski LP, Shah JP, et al. Growing incidence of thyroid carcinoma in recent years: Factors underlying overdiagnosis. *Head Neck*. 2018; 40: 855-866.
- 2▯ Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. *Lancet*. 2016; 388: 2783-2795.
- 3▯ Leboulleux S, Tuttle RM, Pacini F, Schlumberger M. Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance? *Lancet Diabetes Endocrinol*. 2016; 4: 933-942.
- 4▯ Grani G, Lamartina L, Durante C, Filetti S, Cooper DS. Follicular thyroid cancer and Hurthle cell carcinoma: challenges in diagnosis, treatment, and clinical management. *Lancet Diabetes Endocrinol*. 2018; 6: 500-514.
- 5▯ Dubin DT, Taylor RH. The methylation state of poly A-containing messenger RNA from cultured hamster cells. *Nucleic Acids Res*. 1975; 2: 1653-1668.
- 6▯ Lee M, Kim B, Kim VN. Emerging roles of RNA modification: m(6)A and U-tail. *Cell*. 2014; 158: 980-987.
- 7▯ Shi H, Wang X, Lu Z, et al. YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA. *Cell Res*. 2017; 27: 315-328.
- 8▯ Roignant JY, Soller M. m(6)A in mRNA: An Ancient Mechanism for Fine-Tuning Gene Expression. *Trends Genet*. 2017; 33: 380-390.
- 9▯ Lipshitz HD, Claycomb JM, Smibert CA. Post-transcriptional regulation of gene expression. *Methods*. 2017; 126: 1-2.
- 10▯ Gilbert WV, Bell TA, Schaening C. Messenger RNA modifications: Form, distribution, and function. *Science*. 2016; 352: 1408-1412.
- 11▯ Yang Y, Hsu PJ, Chen YS, Yang YG. Dynamic transcriptomic m(6)A decoration: writers, erasers, readers and functions in RNA metabolism. *Cell Res*. 2018; 28: 616-624.
- 12▯ Zhao W, Cui Y, Liu L, et al. METTL3 Facilitates Oral Squamous Cell Carcinoma Tumorigenesis by Enhancing c-Myc Stability via YTHDF1-Mediated m(6)A Modification. *Mol Ther Nucleic Acids*. 2020; 20: 1-12.

- 13 Ianniello Z, Paiardini A, Fatica A. N(6)-Methyladenosine (m(6)A): A Promising New Molecular Target in Acute Myeloid Leukemia. *Front Oncol.* 2019; 9: 251.
- 14 Barbieri I, Tzelepis K, Pandolfini L, et al. Promoter-bound METTL3 maintains myeloid leukaemia by m(6)A-dependent translation control. *Nature.* 2017; 552: 126-131.
- 15 Zhang S, Zhao BS, Zhou A, et al. m(6)A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program. *Cancer Cell.* 2017; 31: 591-606 e596.
- 16 Li Z, Qian P, Shao W, et al. Suppression of m(6)A reader Ythdf2 promotes hematopoietic stem cell expansion. *Cell Res.* 2018; 28: 904-917.
- 17 Hu X, Peng WX, Zhou H, et al. IGF2BP2 regulates DANCER by serving as an N6-methyladenosine reader. *Cell Death Differ.* 2019.
- 18 Niu Y, Lin Z, Wan A, et al. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3. *Mol Cancer.* 2019; 18: 46.
- 19 Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. *Bioinformatics.* 2010; 26: 1572-1573.
- 20 Sun Y, Huang J, Hu J. m6A RNA Methylation Regulators Contribute to Malignant Progression and Have Clinical Prognostic Impact in Gastric Cancer. *Front Oncol.* 2019; 9: 1038.
- 21 Liu Q, Gregory RI. RNAmoD: an integrated system for the annotation of mRNA modifications. *Nucleic Acids Res.* 2019; 47(W1): W548-W555.
- 22 Wu Y, Zhao W, Liu Y, et al. Function of HNRNPC in breast cancer cells by controlling the dsRNA-induced interferon response. *EMBO J.* 2018; 37.
- 23 Pino I, Pio R, Toledo G, et al. Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. *Lung Cancer.* 2003; 41: 131-143.
- 24 Park YM, Hwang SJ, Masuda K, et al. Heterogeneous nuclear ribonucleoprotein C1/C2 controls the metastatic potential of glioblastoma by regulating PDCD4. *Mol Cell Biol.* 2012; 32: 4237-4244.
- 25 Sun W, Xing B, Sun Y, et al. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues. *Mol Cell Proteomics.* 2007; 6: 1798-1808.
- 26 Jia G, Fu Y, Zhao X, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. *Nat Chem Biol.* 2011; 7: 885-887.

- 27☐ Zheng G, Dahl JA, Niu Y, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. *Mol Cell*. 2013; 49: 18-29.
- 28☐ Li Z, Weng H, Su R, et al. FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N(6)-Methyladenosine RNA Demethylase. *Cancer Cell*. 2017; 31: 127-141.
- 29☐ Zhou S, Bai ZL, Xia D, et al. FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting beta-catenin through mRNA demethylation. *Mol Carcinog*. 2018; 57: 590-597.
- 30☐ Yue Y, Liu J, Cui X, et al. VIRMA mediates preferential m(6)A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation. *Cell Discov*. 2018; 4: 10.
- 31☐ Qian JY, Gao J, Sun X, et al. KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner. *Oncogene*. 2019; 38: 6123-6141.
- 32☐ Raffel GD, Mercher T, Shigematsu H, et al. Ott1(Rbm15) has pleiotropic roles in hematopoietic development. *Proc Natl Acad Sci U S A*. 2007; 104: 6001-6006.
- 33☐ Niu C, Zhang J, Breslin P, Onciu M, Ma Z, Morris SW. c-Myc is a target of RNA-binding motif protein 15 in the regulation of adult hematopoietic stem cell and megakaryocyte development. *Blood*. 2009; 114: 2087-2096.
- 34☐ Yang Y, Wang S, Zhang Y, Zhu X. Biological effects of decreasing RBM15 on chronic myelogenous leukemia cells. *Leuk Lymphoma*. 2012; 53: 2237-2244.

Figures

Figure 1

The landscape of m6A RNA methylation regulators in thyroid cancer. A, The heatmap of the expression levels of m6A RNA methylation regulators in thyroid carcinoma from TCGA database. N, normal. T, tumor. Red, up-regulated. Green, down-regulated. B, Violin visualizing the differentially m6A RNA methylation regulators in thyroid carcinoma. Blue, normal. Red, Tumor. C, Spearman correlation analysis of the 13 m6A RNA methylation regulators in thyroid carcinoma. D, The expression levels of m6A RNA methylation regulators in thyroid carcinoma with different clinicopathological characteristics.

Figure 2

Identification of consensus clusters by m6A RNA methylation regulators. A, Consensus clustering cumulative distribution function (CDF) for k = 2 – 9. B, Relative alteration in area under CDF curve for k = 2 – 9. C, Consensus clustering matrix for k = 2. D, Principal component analysis of the total RNA expression profile from TCGA database. E, Kaplan-Meier analysis of overall survival for 450 patients with

thyroid carcinoma from TCGA database. F, Heatmap and clinicopathologic characteristics of the two clusters defined by the m6A RNA methylation regulators consensus expression.

Figure 3

Construction of risk signature with three m6A RNA methylation regulators. A, Univariate Cox analysis of the 13 m6A RNA methylation regulators to identify the genes that significantly correlated with overall survival. B and C, Coefficients of three m6A RNA methylation regulators calculated by LASSO Cox

regression algorithm. D, The relationship between the three m6A RNA methylation regulators expression and clinicopathologic characteristics in high-/low-risk subgroup of thyroid carcinoma patients. E, Kaplan-Meier analysis of overall survival in high-/low-risk subgroup of thyroid carcinoma patients. F, The prediction efficiency of risk signature analyzed by ROC curve.

Figure 4

Differential signaling pathways and cellular processes between the high-risk subgroup and the low-risk subgroup defined by a 3-gene expression signature. A, The highly enriched gene sets in high-risk group analyzed by GSEA. B, Biological processes of differentially expressed genes between the high-risk subgroup and the low-risk subgroup. C, KEGG pathways in which differentially expressed genes were distributed.

Figure 5

Evaluation of prognostic values of risk scores in patients with thyroid carcinoma. A, Univariate Cox analyses of the association between clinicopathological characteristics and overall survival in patients with thyroid carcinoma. B, Multivariate Cox analyses of the association between clinicopathological characteristics and overall survival in patients with thyroid carcinoma.

Figure 6

Kaplan-Meier analysis of overall survival in patients with thyroid carcinoma stratified by age (A and B), gender (C and D), stage (E and F) and tumor size (G and H).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [supplementary.docx](#)